Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome

Katherine W. Lam,1,a Kenneth W. Chow,1,a Jonathan Vo,1 Wei Hou,1 Haifang Li,1 Paul S. Richman,2 Sandeep K. Mallipattu,2 Hal A. Skopicki,2 Adam J. Singer,3 and Tim Q. Duong1,*

1Department of Radiology, Renaissance School of Medicine, Stony Brook University, New York, New York, USA, 2Department of Medicine, Renaissance School of Medicine, Stony Brook University, New York, New York, USA, and 3Department of Emergency Medicine, Renaissance School of Medicine, Stony Brook University, New York, New York, USA

Background. This study investigated continued and discontinued use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) during hospitalization of 614 hypertensive laboratory-confirmed COVID-19 patients.

Methods. Demographics, comorbidities, vital signs, laboratory data, and ACEi/ARB usage were analyzed. To account for confounders, patients were substratified by whether they developed hypotension and acute kidney injury (AKI) during the index hospitalization.

Results. Mortality (22% vs 17%, P > .05) and intensive care unit (ICU) admission (26% vs 12%, P > .05) rates were not significantly different between non-ACEi/ARB and ACEi/ARB groups. However, patients who continued ACEi/ARBs in the hospital had a markedly lower ICU admission rate (12% vs 26%; P = .001; odds ratio [OR] = 0.347; 95% confidence interval [CI], .187–.643) and mortality rate (6% vs 28%; P = .001; OR = 0.215; 95% CI, .101–.455) compared to patients who discontinued ACEi/ARB. The odds ratio for mortality remained significantly lower after accounting for development of hypotension or AKI.

Conclusions. These findings suggest that continued ACEi/ARB use in hypertensive COVID-19 patients yields better clinical outcomes.

Keywords. angiotensin-converting enzyme inhibitors; angiotensin II receptor blockers; troponin; hypotension; acute kidney injury.

Hypertension is a common comorbidity in patients with coronavirus disease 2019 (COVID-19) and has been associated with worse clinical outcomes [1–6]. Because the widely used antihypertensive medications angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) may upregulate ACE2 receptors [7–9], through which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) enters the host cells [10], concerns have been raised as to whether their use may result in increased morbidity and mortality [4, 11–13]. On the other hand, ACE2 has also been shown to have vasodilatory, anti-inflammatory, and antifibrotic effects that could potentially alleviate disease severity [14–16].

Several clinical studies have reported that ACEi/ARB use in COVID-19 patients with hypertension does not worsen COVID-19 disease severity or mortality [16–22]. However, these studies have either focused on ACEi/ARB use prior to hospitalization or did not control for potential clinical interactions for which ACEi/ARB use might be discontinued, such as the development of hypotension or acute kidney injury (AKI). Despite limited data, a number of professional societies [23, 24] have released statements recommending that ACEi/ARBs should be continued in hypertensive COVID-19 patients [25, 26]. This is based, in part, on the belief that these agents serve a beneficial role in treating underlying cardiovascular disease and may preclude further clinical deterioration.

Stony Brook University Hospital, about 40 miles east of New York City, is the largest academic hospital in Suffolk County, serving a population of approximately 1.5 million people and with over 39 000 laboratory-confirmed COVID-19 patients at the time of this analysis. The goal of this study was to investigate the effects of in-hospital continuation and discontinuation of ACEi/ARBs on the clinical outcomes of hypertensive COVID-19 patients, controlling for newly developed hypotension or AKI during hospitalization.
METHODS

Study Population and Data Collection

This retrospective single-center study from Stony Brook University Hospital was approved by the Human Subjects Committee with an exemption for informed consent and a Health Insurance Portability and Accountability Act (HIPAA) waiver. The Stony Brook University Hospital COVID-19 Persons Under Investigation Registry consisted of 6235 patients clinically suspected of COVID-19 infection from 7 February 2020 to 23 May 2020. Confirmation of COVID-19 infection was based on a positive real-time polymerase chain reaction test for SARS-CoV-2 on a nasopharyngeal swab specimen. Clinical data at hospital admission, including demographic information, chronic comorbidities present on admission, vital signs, laboratory blood tests, and outcomes, were extracted individually from the patients’ electronic medical records. The primary outcome was in-hospital mortality and the secondary outcome was intensive care unit (ICU) admission.

Patients were divided into 2 groups; hypertensive patients: (1) that were not taking ACEi/ARBs at home (group A), and (2) taking ACEi/ARBs at home. The latter group was further divided into those who discontinued ACEi/ARBs during their hospital stay (group B), and those who continued ACEi/ARBs during their hospital stay (group C).

Statistical Analysis

Frequencies and percentages for categorical variables between the ACEi/ARB groups were compared using \( \chi^2 \) tests. Continuous variables, expressed as median (interquartile range [IQR]), were compared between groups using nonparametric Mann-Whitney \( U \) tests. Bonferroni correction for multiple comparisons was used where appropriate. Mortality and ICU admission rates were compared between group B (ACEi/ARB discontinued) and C (ACEi/ARB continued) with \( \chi^2 \) tests (unadjusted without covariates) and with logistic regression (adjusted with covariates). Age, sex, and significantly different comorbidities between groups were included in logistic regression models as covariates for controlling confounding effects. Analyses were also stratified by hypotension and AKI status. \( P \) values < .05 were considered statistically significant. All statistical analyses were performed using SPSS version 26 (IBM Corporation).

RESULTS

Patient Selection

The Stony Brook University Hospital COVID-19 Persons Under Investigation Registry consisted of 6235 patients clinically suspected of COVID-19 infection who presented to the emergency department between 7 February and 23 May 2020, of which 2789 were confirmed to be COVID-19 positive (Figure 1). There were 875 patients in this cohort who had a history of hypertension. We excluded 211 patients who were discharged directly from the emergency department, 5 who were transferred to other hospitals, and 45 whose discharge status was still unknown as of 23 May 2020. This yielded a final sample size of 614 hospitalized COVID-19 patients with a history of hypertension. Group A consisted of 279 hypertensive patients who did not take ACEi/ARBs prior to admission, of whom 224 did not require ICU care (ie, general admission) and 55 required ICU care at any point during hospitalization. There were 62 deaths in this group. Group B consisted of 171 hypertensive patients who discontinued their home medications, ACEi/ARBs, in the hospital, of whom 126 did not require ICU care and 45 required ICU care. There were 48 deaths in this group. Group C consisted of 164 hypertensive patients who continued their home medications, ACEi/ARBs, in the hospital, of whom 144 did not require ICU care and 20 required ICU care. There were 10 deaths in this group.

Patient Demographics, Comorbidities, and Laboratory Tests

The median age of patients in the non-ACEi/ARB group was older than that of the ACEi/ARB group (73 years [IQR, 62–83] versus 68 years [IQR, 58–79], \( P = .004; \) Table 1). Sex and ethnic identity were not significantly different between groups \( (P > .05) \). The prevalence of diabetes mellitus was higher in those in the ACEi/ARB group \( (P = .01) \) but lower in those with chronic kidney disease (CKD) at baseline \( (P = .001) \), whereas the prevalence of asthma, history of coronary heart disease, chronic obstructive pulmonary disease, and cancer were not significantly different between groups \( (P > .05) \). Note that the prevalence of CKD in our hypertensive COVID-19 patient cohort was higher than that for all COVID-19 patients in general \( [27] \) as expected.

Hematocrit \( (P = .003) \), sodium \( (P = .001) \), D-dimer \( (P = .003) \), and troponin \( (P = .005) \) levels were significantly different between the non-ACEi/ARB and ACEi/ARB groups after correction for multiple comparisons (Table 2). Elevated D-dimer and troponin levels have been previously associated with a more severe COVID-19 disease course \( [7, 18–20] \).

Mortality

For hypertensive COVID-19–positive patients, the mortality was not statistically different between the non-ACEi/ARB and ACEi/ARB groups (unadjusted \( P = .127 \) without covariates, adjusted \( P = .336 \) with covariates; Figure 2A). By contrast, patients in the ACEi/ARB group who continued these medications in the hospital (group C) had a significantly lower mortality rate compared to those who discontinued ACEi/ARB in the hospital (group B) (unadjusted \( P = .001 \), adjusted \( P = .001 \); Figure 2B). The odds ratio was 0.215 (95% confidence interval, .101–.455).

The percentage of hospitalized patients who developed hypotension subsequent to the index hospitalization was higher in the discontinued ACEi/ARG group than the continued ACEi/ARG group (42.7%, 73/171 vs 15.69%, 26/164, respectively; \( P = .001 \)). The percentage of hospitalized patients who
developed AKI subsequent to the index hospitalization was higher in the discontinued ACEi/ARB group than the continued ACEi/ARB group (59.1%, 101/171 vs 18.9%, 31//164, respectively; \( P = .001 \)).

Thus, mortality was stratified with respect to development of hypotension and AKI (Table 3). In patients that developed in-hospital hypotension, there was no significant difference in mortality between continuing or discontinuing ACEi/ARBs (\( P > .05 \)). In contrast, patients who did not develop hypotension and continued ACEi/ARBs had a significantly lower mortality rate than those who discontinued (unadjusted \( P = .001 \), adjusted \( P < .017 \)). Similarly, in patients who developed AKI, there was no significant difference in mortality between continuing or discontinuing ACEi/ARBs in the hospital (unadjusted \( P = .050 \), adjusted \( P = .117 \)). In patients who did not develop AKI, those who continued ACEi/ARBs had a significantly lower mortality rate than those who discontinued (unadjusted \( P = .001 \), adjusted \( P = .011 \)).

### ICU Admission

The ICU admission rates were not significantly different between the non-ACEi/ARB and ACEi/ARB groups (unadjusted \( P = .923 \), adjusted \( P = .391 \); Figure 3A). By contrast, the ICU admission rate was twice as high in the group that discontinued ACEi/ARBs compared to the group that continued (unadjusted \( P = .001 \), adjusted \( P = .001 \); Figure 3B).

ICU admission was also stratified with respect to the development of hypotension or AKI (Table 4). In the hypotension and nonhypotension groups, there were no differences in ICU admission rates between continuation versus discontinuation of ACEi/ARBs in the hospital (\( P > .05 \)). Similarly, in the group that developed AKI, there was no difference in ICU admission rates between continuing or discontinuing ACEi/ARBs in the hospital (\( P > .05 \)). However, in patients who did not develop AKI, those who continued ACEi/ARBs had a significantly lower mortality rate than those who discontinued these agents (unadjusted \( P < .041 \), adjusted \( P = .043 \)).
Table 1. Characteristics of Patients Who Did Not Receive ACEi/ARB (Group A) and Who Did Receive ACEi/ARB (Groups B and C)

| Demographics                  | Non-ACEi/ARB (Group A, n = 279) | ACEi/ARB (Groups B + C, n = 335) | P Value |
|-------------------------------|---------------------------------|----------------------------------|---------|
| Age, y, median (IQR)          | 73 (62–83)                      | 68 (58–79)                       | **0.004** |
| Hospital stay duration, d, median (IQR) | 6 (3–11)                      | 7 (4–12)                         | NS      |
| Sex                           |                                 |                                  |         |
| Female                        | 130 (46.6)                      | 148 (43.6)                       | NS      |
| Male                          | 149 (53.4)                      | 189 (56.4)                       |         |
| Ethnicity                     |                                 |                                  |         |
| White                         | 176 (63.1)                      | 200 (59.7)                       | NS      |
| African American              | 25 (9.0)                        | 27 (8.1)                         |         |
| Asian                         | 9 (3.2)                         | 13 (3.9)                         | NS      |
| Native American               | 3 (1.1)                         | 0 (0)                            |         |
| Other                         | 66 (23.6)                       | 95 (28.4)                        |         |
| Comorbidities                 |                                 |                                  |         |
| Diabetes                      | 98 (35.1)                       | 152 (45.4)                       | **0.010** |
| Asthma                        | 11 (3.9)                        | 22 (6.6)                         | NS      |
| Coronary heart disease        | 66 (23.7)                       | 82 (24.6)                        | NS      |
| COPD                          | 45 (16.1)                       | 37 (11.0)                        | **0.065** |
| Heart failure                 | 44 (15.8)                       | 38 (11.3)                        | NS      |
| Cancer                        | 39 (14.0)                       | 32 (9.6)                         | **0.088** |
| Chronic kidney disease        | 63 (23.4)                       | 30 (9.0)                         | **0.001** |

Values are No. (%) except where indicated. Categorical comparison used χ² tests and continuous comparison used Mann-Whitney U tests. Significant values in which P < .05 are noted in bold.

Note that the prevalence of CKD in our hypertensive COVID-19 patient cohort was higher than that for all COVID-19 patients [27]. Although the non-ACEi/ARB group was older than the ACEi/ARB group, our statistical analysis included age as a covariate with logistic regression to ensure our primary finding was not due to age per se.

Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; NS, not significant.

**DISCUSSION**

This study analyzed in-hospital ACEi/ARB use in hypertensive COVID-19 patients and the associated confounding variables that likely resulted in discontinuation of ACEi/ARB use. The major findings are: (1) hypertensive COVID-19 patients who continued ACEi/ARBs in the hospital had lower in-hospital mortality and ICU admission compared to those who discontinued ACEi/ARBs; (2) for in-hospital mortality, this conclusion remained true after controlling for confounders by excluding patients who developed hypotension or AKI for which ACEi/ARBs were withheld on treatment of hypotension or AKI. Patients who developed hypotension or AKI had a higher mortality rate. It is important to control for these 2 confounders. In the absence of hypotension or AKI, patients who continued ACEi/ARBs had lower mortality and ICU admission rates compared to those who discontinued them, further supporting that continued ACEi/ARB use may have beneficial effects. To our knowledge, this study reports the largest cohort of hospitalized hypertensive COVID-19 patients on ACEi/ARBs from a large academic hospital in the United States.
Table 2. Clinical Variables of Patients Who Did Not Receive ACEi/ARB (Group A) and Who Did Receive ACEi/ARB (Groups B and C) at Admission

| Variable                        | Non-ACEi/ARB, Median (IQR) (Group A, n = 279) | ACEi/ARB, Median (IQR) (Groups B + C, n = 335) | P Value |
|---------------------------------|-----------------------------------------------|-----------------------------------------------|---------|
| Heart rate, beat/min            | 91 (79–107)                                   | 94 (80–106)                                   | NS      |
| Respiratory rate, /min          | 20 (18–24)                                    | 20 (18–24)                                    | NS      |
| O2 saturation, %                | 95 (92–97)                                    | 94 (91–96)                                    | NS      |
| Fraction of inspired O2, %     | 50 (50–100)                                   | 50 (40–50)                                    | .053    |
| Arterial pressure of O2, mmHg  | 79 (62–103)                                   | 75 (61–99)                                    | NS      |
| Systolic blood pressure, mmHg  | 128 (115–149)                                 | 131 (113–148)                                 | NS      |
| Diastolic blood pressure, mmHg | 74 (64–83)                                    | 74 (65–81)                                    | NS      |
| Mean arterial pressure, mmHg   | 91 (82–102)                                   | 92 (82–101)                                   | NS      |
| Temperature, °C                 | 370 (36.7–376)                                | 371 (36.8–377)                                | .016    |
| Hematology                      |                                               |                                               |         |
| Leukocytes, /µL                 | 6.9 (4.9–9.2)                                 | 7.3 (5.5–9.9)                                 | NS      |
| Lymphocytes, %                  | 12.1 (7.8–17.6)                               | 12.8 (7.5–18.9)                               | NS      |
| Hematocrit, %                   | 39.0 (33.9–43.4)                              | 40.5 (36.0–43.9)                              | .003    |
| Chemistry                       |                                               |                                               |         |
| Bicarbonate, mEq/L              | 23.5 (21.0–26.0)                              | 23.0 (21.0–26.0)                              | NS      |
| Creatinine, mg/dL               | 1.1 (0.9–1.8)                                 | 1.1 (0.8–1.5)                                 | .086    |
| Potassium, mEq/L                | 4.2 (3.9–4.6)                                 | 4.2 (3.8–4.6)                                 | NS      |
| Sodium, mEq/L                   | 138 (135–140)                                 | 136 (133–139)                                 | .001    |
| pH                              | 7.4 (7.3–7.5)                                 | 7.4 (7.3–7.5)                                 | NS      |
| Inflammatory markers            |                                               |                                               |         |
| Alanine aminotransferase, U/L   | 24.0 (15.0–41.0)                              | 28.0 (16.0–42.0)                              | NS      |
| Aspartate aminotransferase, U/L | 37 (26–62)                                    | 38 (26–56)                                    | NS      |
| Brain natriuretic peptide, pg/mL| 630 (143–3115)                                | 451 (86–1517)                                 | .010    |
| C-reactive protein, mg/dL       | 75 (2.9–14.1)                                 | 7.0 (3.1–13.6)                                | NS      |
| D-dimer, ng/mL                  | 450 (268–911)                                 | 380 (220–700)                                 | .003    |
| Ferritin, nm/mL                 | 691 (298–1358)                                | 602 (302–1322)                                | NS      |
| Lactate dehydrogenase, U/L      | 345 (260–461)                                 | 335 (257–439)                                 | NS      |
| Procalcitonin, ng/mL            | 0.2 (0.1–0.4)                                 | 0.2 (0.1–0.4)                                 | NS      |
| Troponin, ng/mL                 | Mean (IQR)                                    | Mean (SD)                                     |         |
|                                 | 0.0 (0.0–0.0)                                 | 0.0 (0.0–0.0)                                 | .005    |
|                                 | 0.05 (0.162)                                  | 0.03 (0.156)                                  |         |

Values are median (IQR) and statistical test employed Mann-Whitney U test. P values displayed are without Bonferroni correction. Significant values in which P < .05 are noted in bold. Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; IQR, interquartile range; NS, not significant.

*After Bonferroni correction for multiple comparisons, hematocrit, plasma sodium, D-dimer, and troponin remained significantly different between group.

Figure 2.  A, Mortality of non-ACEi/ARB (group A patients) and ACEi/ARB (group B + C patients). P = .127 using χ² test. P = .336 with adjustment for age, sex, history of chronic kidney disease, and diabetes using logistic regression (OR = 0.811; 95% CI, 0.529–1.243). B, Mortality of ACEi/ARB discontinued in the hospital (group B patients) and ACEi/ARB continued in the hospital (group C patients). P = .001 using χ² test. P = .001 with adjustment for age, sex, history of heart failure, chronic obstructive pulmonary disease, and asthma (OR = 0.215; 95% CI, .101–.455). Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CI, confidence interval; OR, odds ratio.
The mechanisms by which ACEi and ARBs may exert their beneficial effects in hypertensive COVID-19 patients are unknown. The continuation of ACEi/ARBs during hospitalization may blunt the adverse effects of hypertension, a well-known risk factor for mortality in COVID-19 [26]. ACEi/ARBs have cardioprotective effects in postmyocardial infarction and heart failure patients by reducing myocardial wall stress [28, 29]. Additionally, ACEi/ARBs have been shown to reduce microvascular complications in patients with cardiac, cerebrovascular, and renal comorbidities [30, 31]. Experimentally, ACEis and ARBs have the ability to upregulate ACE2, which leads to the degradation of angiotensin II and the increased formation of angiotensin 1–7; the latter is thought to have beneficial vasodilatory, anti-inflammatory, and antifibrotic effects [14]. It is also interesting to speculate that ACEi/ARBs may play a role in ameliorating the detrimental effects of the cytokine storm seen during the immune response to SARS-CoV-2 [32, 33], a state that has been linked to the proinflammatory effects of angiotensin II. Finally, ARBs have been shown to prevent aggravation of acute lung injury in mice infected with the closely related betacoronavirus SARS-CoV-1, suggesting a primary pulmonary protective role [34].

Finally, it is worth noting that the reasons for stopping ACEi/ARBs were undoubtedly complex with multiple documented and undocumented possibilities. In clinical practice, hypotension and AKI are the most frequent justifications for

| Table 3. Mortality Rates in Patients who Continued ACEi/ARB Use During Hospitalization Versus Patients Who Discontinued ACEi/ARB Use During Hospitalization, Stratified by Hypotension and AKI |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Stratification  | ACEi/ARB        |                | Unadjusted      | Adjusted        |                    |
|                 | Discontinued,   | Continued,     | PValuea         | PValueb         | Odds Ratio        |
|                 | n/N (%) (Group B) | n/N (%) (Group C) |                |                 | (95% CI)b         |
| Without         | 48/171 (28.07) | 10/164 (6.09)  | .001            | .001            | 0.215 (.101–.455) |
| substratification | (Figure 2B)     | (205.87)       |                 |                 |                    |
| Hypotension     | 35/73 (47.34)  | 7/26 (26.92)   | .063            | .183            | 0.489 (.170–1.402) |
| Nonhypotension  | 12/98 (13.27)  | 3/138 (2.17)   | .001            | .017            | 0.172 (.040–.730) |
| AKI             | 35/101 (34.65) | 5/31 (16.12)   | .050            | .117            | 0.423 (.144–1.242) |
| Non-AKI         | 13/70 (18.57)  | 5/133 (3.75)   | .001            | .011            | 0.224 (.071–.708) |
| Data are number of deaths/number of patients, n/N (%). Significant values in which P < .05 are noted in bold. |
| Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensin II receptor blocker; CI, confidence interval. |
| aχ² tests. |
| bLogistic regression with adjustment for age, sex, history of heart failure, chronic obstructive pulmonary disease, and asthma (comorbidities that were significantly different between groups B and C). |

The mechanisms by which ACEi and ARBs may exert their beneficial effects in hypertensive COVID-19 patients are unknown. The continuation of ACEi/ARBs during hospitalization may blunt the adverse effects of hypertension, a well-known risk factor for mortality in COVID-19 [26]. ACEi/ARBs have cardioprotective effects in postmyocardial infarction and heart failure patients by reducing myocardial wall stress [28, 29]. Additionally, ACEi/ARBs have been shown to reduce microvascular complications in patients with cardiac, cerebrovascular, and renal comorbidities [30, 31]. Experimentally, ACEis and ARBs have the ability to upregulate ACE2, which leads to the degradation of angiotensin II and the increased formation of angiotensin 1–7; the latter is thought to have beneficial vasodilatory, anti-inflammatory, and antifibrotic effects [14]. It is also interesting to speculate that ACEi/ARBs may play a role in ameliorating the detrimental effects of the cytokine storm seen during the immune response to SARS-CoV-2 [32, 33], a state that has been linked to the proinflammatory effects of angiotensin II. Finally, ARBs have been shown to prevent aggravation of acute lung injury in mice infected with the closely related betacoronavirus SARS-CoV-1, suggesting a primary pulmonary protective role [34].

Finally, it is worth noting that the reasons for stopping ACEi/ARBs were undoubtedly complex with multiple documented and undocumented possibilities. In clinical practice, hypotension and AKI are the most frequent justifications for

| Figure 3. A, ICU admission rates of non-ACEi/ARB (group A patients) and ACEi/ARB (group B + C patients). P = .923 using χ² test. P = .391 with adjustment for age, sex, history of chronic kidney disease, and diabetes using logistic regression (OR = 0.852; 95% CI, .547–1.286). B, ICU admission rates of ACEi/ARB discontinued in the hospital (group B patients) and ACEi/ARB continued in the hospital (group C patients). P = .001 using χ² test. P = .001 with adjustment for age, sex, history of heart failure, chronic obstructive pulmonary disease, and asthma (OR = 0.347; 95% CI, 1.87–6.43). Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CI, confidence interval; ICU, intensive care unit; OR, odds ratio. |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| A | B |
| Unadjusted P = .923 | Unadjusted P = .001 |
| Adjusted P = .391 | Adjusted P = .001 |
| % ICU admission | % ICU admission |
| Non-ACEi/ARB | ACEi/ARB |
| (n = 279) | (n = 335) |
| 19.71% | 19.40% |
| 25.0% | 25.0% |
| 15.0% | 15.0% |
| 10.0% | 10.0% |
| 5.0% | 5.0% |
| 0.0% | 0.0% |

| % ICU admission | % ICU admission |
| Non-ACEi/ARB | ACEi/ARB |
| (n = 171) | (n = 164) |
| 26.32% | 12.20% |
| 30.0% | 25.0% |
| 20.0% | 20.0% |
| 15.0% | 15.0% |
| 10.0% | 10.0% |
| 5.0% | 5.0% |
| 0.0% | 0.0% |
stopping ACEi/ARBs and there did not appear to be any indication that the current pandemic altered that paradigm. However, this is a retrospective study and the decision to continue or discontinue ACEi/ARB use was part of standard clinical care.

This study has several limitations. It was a retrospective single-center study. Laboratory values were not reassessed in patients who continued or discontinued ACEi/ARBs. Moreover, the difference between ACEi and ARB use could not be resolved due to the limited sample size. Although ACEis and ARBs have similar mechanisms of action, their effects may need to be studied separately. This study did not account for when ACEi/ARBs were discontinued for individual patients during their hospital stay. The current sample size did not allow for substratification based on how long the patients were on these medications before they were discontinued. Individual chart review indicated that hypotension and AKI were the main documented reasons for ACEi/ARB discontinuation. However, in some instances, justification could not be discerned. Moreover, early on in the pandemic, uncertainty existed as to whether ACEi/ARBs were harmful so individual practitioners may have reflexively held these medications without indicating their justification. This contribution is beyond the analysis of the present investigation.

CONCLUSIONS

These findings not only confirm that ACEi/ARB use does not worsen clinical outcomes in COVID-19 patients with a history of hypertension, but also suggest that COVID-19 patients who are on ACEi/ARBs should continue these medications in the hospital as they may have beneficial effects, as long as these patients do not develop hypotension or AKI.

Table 4. ICU Admission Rates in Patients Who Continued ACEi/ARB Use During Hospitalization Versus Patients Who Discontinued ACEi/ARB Use During Hospitalization, Stratified by Hypotension and AKI

| Stratification                      | ACEi/ARB Discontinued, n/N (%) (Group B) | ACEi/ARB Continued, n/N (%) (Group C) | Unadjusted P Value* | Adjusted P Valueb | Odds Ratio (95% CI)b |
|------------------------------------|-----------------------------------------|---------------------------------------|---------------------|-------------------|---------------------|
| Without substratification          | 45/171 (26.3)                           | 20/164 (12.2)                         | .001                | .001              | 0.347 (0.187–0.643) |
| Hypotension                        | 38/73 (52.1)                            | 8/26 (30.8)                           | .062                | .057              | 0.349 (0.118–1.033) |
| Nonhypotension                     | 7/98 (7.1)                              | 12/138 (8.7)                          | .666                | .912              | 1.059 (0.382–2.983) |
| AKI                                | 31/101 (30.7)                           | 7/31 (22.6)                           | .383                | .149              | 0.474 (0.171–1.308) |
| Non-AKI                            | 14/70 (20)                             | 13/133 (9.8)                          | .041                | .043              | 0.412 (0.175–0.971) |

Data are number of deaths/number of patients, n/N (%). Significant values in which P < .05 are noted in bold.

Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensin II receptor blocker; CI, confidence interval; ICU, intensive care unit.

*χ² test.

bLogistic regression with adjustment for age, sex, history of heart failure, chronic obstructive pulmonary disease, and asthma (comorbidities that were significantly different between groups).

Notes

Acknowledgments. We thank all health care professionals for their hard work at the front line of the pandemic.

Author contributions. K. W. L., K.W.C., and J. V. carried out data collection, data analysis, literature research, writing/editing manuscript. W. H. and H. L. analyzed data. P. S. R., S. K. M., H. A. S., and A. J. S. discussed and edited the manuscript. T. Q. D. carried out conceptualization, discussion, editing manuscript, and supervision.

Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382:1708–20.
2. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382:727–33.
3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507–13.
4. Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; 5:811–18.
5. Grasselli G, Zaninelli A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020; 323:1574–81.
6. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020; 323:2052–9.
7. Song J, Hu B, Qu H, et al. Upregulation of angiotensin converting enzyme 2 by shear stress reduced inflammation and proliferation in vascular endothelial cells. Biochem Biophys Res Commun 2020; 525:812–8.
8. Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005; 111:2605–10.
9. Nicin L, Abplanalp WT, Mellentin H, et al. Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts. Eur Heart J 2020; 41:1804–6.
10. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181:271–80.e8.
11. Fang L, Karakiulakis G, Roth R. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020; 8:e21.
12. Ruocco G, Feola M, Palazzuoli A. Hypertension prevalence in human coronavirus disease: the role of ACE system in infection spread and severity. Int J Infect Dis 2020; 95:373–5.
13. Li G, Hu R, Zhang X. Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension. Hypertens Res 2020; 43:588–90.
14. Tomasoni D, Italia L, Adamo M, et al. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease [published online ahead of print 15 May 2020]. Eur J Heart Fail doi: 10.1002/ejhf.1871.
15. Danser AHJ, Epstein M, Batlle D. Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension 2020; 75:1382–5.
16. Rossi GP, Sanga V, Barton M. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. Elife 2020; 9:e57278.
17. Sriram K, Insel PA. Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence. Clin Pharmacol Ther 2020; 108:236–41.
18. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19. N Engl J Med 2020; 382:2441–8.
19. Yang G, Tan Z, Zhou L, et al. Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study. Hypertension 2020; 76:51–8.
20. Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol 2020; 5:825–30.
21. Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 2020; 9:757–60.
22. Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 2020; 126:1671–81.
23. American College of Physicians. COVID-19: An ACP physician’s guide and resources, 2020. https://www.acponline.org/cme-moc/online-learning-center/covid-19-an-ACP-physicians-guide-resources. Accessed 24 July 2020.
24. American College of Cardiology. HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19, 2020. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19. Accessed 24 July 2020.
25. Iacurcaro G, Borghi C, Cicero AFG, et al. Renin-angiotensin system inhibition in cardiovascular patients at the time of COVID19: much ado for nothing? A statement of activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension. High Blood Press Cardiovasc Prev 2020; 27:105–8.
26. Singh AK, Gupta R, Misra A. Comorbidities in COVID-19: outcomes in hypertensive cohort and controversies with renin angiotensin system blockers. Diabetes Metab Syndr 2020; 14:283–7.
27. Singer AJ, Morley E, Meyers K, et al. Cohort of four thousand four hundred four persons under investigation for COVID-19 in a New York hospital and predictors of ICU care and ventilation [published online ahead of print 11 May 2020]. Ann Emerg Med 2020 doi: 10.1016/j.annemergmed.2020.05.011.
28. Fother MD, Yusuf S, Kobler L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355:1575–81.
29. Ferrario CM. Cardiac remodelling and RAS inhibition. Ther Adv Cardiovasc Dis 2016; 10:162–71.
on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334:939–45.

31. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62:263–71.

32. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 2007; 21:20–7.

33. Adão R, Guzik TJ. Inside the heart of COVID-19. Cardiovasc Res 2020; 116:e59–61.

34. Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertens Res 2020; 43:648–54.